PT1937221E - Formulação de efeito retardado para pralnacasan - Google Patents

Formulação de efeito retardado para pralnacasan Download PDF

Info

Publication number
PT1937221E
PT1937221E PT06805947T PT06805947T PT1937221E PT 1937221 E PT1937221 E PT 1937221E PT 06805947 T PT06805947 T PT 06805947T PT 06805947 T PT06805947 T PT 06805947T PT 1937221 E PT1937221 E PT 1937221E
Authority
PT
Portugal
Prior art keywords
pralnacasan
type
retard formulation
releases
layer
Prior art date
Application number
PT06805947T
Other languages
English (en)
Inventor
Caren Soennichsen
Roland Wesch
Heiko Meier
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of PT1937221E publication Critical patent/PT1937221E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
PT06805947T 2005-10-08 2006-09-29 Formulação de efeito retardado para pralnacasan PT1937221E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102005048293A DE102005048293A1 (de) 2005-10-08 2005-10-08 Retardformulierung für Pralnacasan

Publications (1)

Publication Number Publication Date
PT1937221E true PT1937221E (pt) 2009-04-17

Family

ID=37764039

Family Applications (1)

Application Number Title Priority Date Filing Date
PT06805947T PT1937221E (pt) 2005-10-08 2006-09-29 Formulação de efeito retardado para pralnacasan

Country Status (28)

Country Link
US (1) US8231904B2 (pt)
EP (1) EP1937221B1 (pt)
JP (1) JP2009511441A (pt)
KR (1) KR101362679B1 (pt)
CN (1) CN101277683B (pt)
AT (1) ATE422354T1 (pt)
AU (1) AU2006301573B2 (pt)
BR (1) BRPI0617184A2 (pt)
CA (1) CA2624838C (pt)
CY (1) CY1109131T1 (pt)
DE (2) DE102005048293A1 (pt)
DK (1) DK1937221T3 (pt)
ES (1) ES2322202T3 (pt)
HK (1) HK1124531A1 (pt)
HR (1) HRP20090254T1 (pt)
IL (1) IL190511A (pt)
MA (1) MA29803B1 (pt)
ME (1) ME01735B (pt)
MY (1) MY146552A (pt)
NO (1) NO339360B1 (pt)
NZ (1) NZ567268A (pt)
PL (1) PL1937221T3 (pt)
PT (1) PT1937221E (pt)
RS (1) RS50777B (pt)
RU (1) RU2419419C2 (pt)
SI (1) SI1937221T1 (pt)
WO (1) WO2007042160A1 (pt)
ZA (1) ZA200802031B (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2575860T3 (es) 2010-07-09 2016-07-01 Bhv Pharma, Inc. Sistema de administración de liberación inmediata/retardada de combinación para productos farmacéuticos de semivida corta que incluyen remogliflozina
CH705678B1 (de) * 2010-08-13 2016-03-15 Euro Celtique Sa Verwendung von Bindemitteln zur Herstellung von lagerungsstabilen Formulierungen.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204261B1 (en) * 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
US5085865A (en) * 1989-04-12 1992-02-04 Warner-Lambert Company Sustained release pharmaceutical preparations containing an analgesic and a decongestant
IT1264696B1 (it) * 1993-07-09 1996-10-04 Applied Pharma Res Forme farmaceutiche destinate alla somministrazione orale in grado di rilasciare sostanze attive a velocita' controllata e differenziata
FR2772615B1 (fr) * 1997-12-23 2002-06-14 Lipha Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
UA81224C2 (uk) * 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
CN1524526A (zh) * 2003-03-02 2004-09-01 颖 王 尼群地平双层缓释制剂
US20050013863A1 (en) 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
CN1579401A (zh) * 2003-08-11 2005-02-16 李亦武 一种止咳平喘药物新剂型及制备方法
US7611728B2 (en) * 2003-09-05 2009-11-03 Supernus Pharmaceuticals, Inc. Osmotic delivery of therapeutic compounds by solubility enhancement
WO2005048979A2 (en) * 2003-10-06 2005-06-02 Torrent Pharmaceuticals Limited Pharmaceutical composition having casing with multiple micro tablets
WO2005051350A2 (en) * 2003-10-28 2005-06-09 Torrent Pharmaceuticals Limited Water dispersible tablet

Also Published As

Publication number Publication date
CN101277683B (zh) 2013-03-20
KR101362679B1 (ko) 2014-02-13
CN101277683A (zh) 2008-10-01
CA2624838C (en) 2013-11-19
NO339360B1 (no) 2016-12-05
ATE422354T1 (de) 2009-02-15
ME01735B (me) 2010-08-31
ES2322202T3 (es) 2009-06-17
EP1937221B1 (de) 2009-02-11
HRP20090254T1 (en) 2009-06-30
IL190511A (en) 2011-05-31
CA2624838A1 (en) 2007-04-19
MA29803B1 (fr) 2008-09-01
RS50777B (sr) 2010-08-31
CY1109131T1 (el) 2014-07-02
KR20080054394A (ko) 2008-06-17
HK1124531A1 (en) 2009-07-17
NZ567268A (en) 2010-08-27
WO2007042160A1 (de) 2007-04-19
IL190511A0 (en) 2008-11-03
BRPI0617184A2 (pt) 2011-07-12
SI1937221T1 (sl) 2009-06-30
NO20081896L (no) 2008-04-21
US8231904B2 (en) 2012-07-31
ZA200802031B (en) 2009-08-26
AU2006301573B2 (en) 2013-01-10
RU2008113381A (ru) 2009-10-20
RU2419419C2 (ru) 2011-05-27
DE102005048293A1 (de) 2007-04-12
DK1937221T3 (da) 2009-06-15
DE502006002851D1 (de) 2009-03-26
PL1937221T3 (pl) 2009-06-30
AU2006301573A1 (en) 2007-04-19
MY146552A (en) 2012-08-30
US20080279934A1 (en) 2008-11-13
JP2009511441A (ja) 2009-03-19
EP1937221A1 (de) 2008-07-02

Similar Documents

Publication Publication Date Title
WO2007100535A3 (en) Oxyntomodulin derivatives
MX2009001294A (es) Granulo y tableta que se desintegra por vía oral que comprende oxicodona.
MX2009006536A (es) Compuestos de heteroaril-heteroarilo como inhibidores de cdk para el tratamiento de cancer, inflamacion e infecciones virales.
NZ620326A (en) Cd37 immunotherapeutic combination therapies and uses thereof
TW200716600A (en) Substituted arylpyrazoles
TW200740956A (en) Organic electroluminescent devices
WO2009032898A3 (en) Compact input device
TNSN08400A1 (en) Organic compounds and their uses
WO2009068214A3 (de) Heteroaryl-substituierte piperidine
WO2007098203A3 (en) Conductive polymers from precursor polymers, method of making, and use thereof
WO2006105538A3 (en) Methods and compositions for treating il-21 related pathologies
MX2012007548A (es) Activadores de tienen [2,3-b] piridindiona de proteina quinasa activada con amp y usos terapeuticos de los mismos.
GB2456466A (en) Sanitizing surfaces
TW200730966A (en) Display device
WO2008138943A3 (en) Prophylactic and therapeutic use of sirtuin inhibitors in tnf-alpha mediated pathologies
IL208463A (en) 2-Trotocyclic-Pirol compounds combined, pharmaceutical preparations containing them and their use in the prevention or treatment of diabetes or obesity
WO2007009701A3 (en) Use of substituted pyrazole compounds and combinations thereof for the treatment of the metabolic syndrome
MX2009010231A (es) Una tableta que tiene estabilidad mejorada con al menos dos ingredientes activos.
UA95627C2 (ru) Аминотиазолы и их применение
HRP20090254T1 (en) Retard formulation for pralnacasan
ES2351403T8 (es) Procedimiento para reducir el contenido de dioxinas de la arcilla blanqueante
WO2008009804A3 (fr) Tablette multicouche à couches de fragmentation
WO2007136619A3 (en) Solution processible materials and their use in electronic devices
MX2007010322A (es) Extractos de planta y metodos y usos de los mismos.
CL2007002981A1 (es) Composicion farmaceutica que contiene 75 mg del isomero dextrogiro de clopidogrel y 300 mg de triflusal, util en el tratamiento de enfermedades tromboembolicas.